📈 Jumpstart Signal Watchlist — July 22, 2026

🏢 What they do: Bioventus Inc. is a global medical device company that develops and commercializes clinically proven, minimally invasive products to relieve pain and address musculoskeletal challenges by enhancing the body's natural healing process .
- 🎯 Current $11.63 is 15% below 3yr high $13.71 · ⏳ SMA200 $8.57 (current price $11.63 is above) · 💰 Market Cap $783M
- BVS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 43/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 200% (>20%); ROE 15% (>15%); Near-high ROE setup (52wk high + ROE); PEG ratio 0.14 (<1.5).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA50 (11.9%)
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (58) — BEARISH
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Bioventus shares rise after Medicare reverses reimbursement cuts — Investing.com.
🤖 Bioventus shares jumped as much as 13% after CMS reversed previously issued reimbursement cuts for its non-invasive bone growth stimulators. The reversal should improve reimbursement economics for the company’s products, which is favorable for revenue expectations and stock sentiment.
✅ Bioventus (NASDAQ:BVS) Reaches New 12-Month High — MarketBeat.
🤖 The article reports Bioventus hit a new 12-month high and notes continued favorable analyst positioning, including a consensus Buy rating and price target above the current share price. That combination is generally supportive for the stock.
🍭 Bonus (B): 0/10 — Surgical & Medical Instruments

🏢 What they do: Pitney Bowes is a technology-driven shipping, mailing, and financial services company. It provides tools and services such as postage meters, mailing equipment, shipping software, presort mail services, and parcel/shipping management solutions for businesses of all sizes.
- 🎯 Current $17.99 is 3% below 3yr high $18.51 · ⏳ SMA200 $12.40 (current price $17.99 is above) · 💰 Market Cap $3.6B
- PBI shows decent technicals supported by positive sentiment.

💎 Quality (Q): 44/60
- 🏦 Low drawdown (11.9% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 105% (>20%); PEG ratio 0.16 (<1.5).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Pitney Bowes stock hits 52-week high at 18.15 USD — Investing.com.
🤖 The article says PBI hit a 52-week high, reflecting strong recent share price momentum and investor confidence. It also notes earlier positive developments such as strong Q1 earnings, raised full-year guidance, and a credit facility extension, which support a constructive view on the stock.
✅ Pitney Bowes (NYSE:PBI) Sets New 1-Year High — MarketBeat.
🤖 This report says PBI reached a new 52-week high as buying interest remained strong. While it mentions the stock’s current Hold consensus and price target, the main takeaway is still bullish price action.
✅ Pitney Bowes Hits a 52-Week High: Should Investors Buy the Stock Now — Zacks.com.
🤖 The article highlights that PBI reached a new 52-week high and frames the company as benefiting from improving business fundamentals. It is positive for the stock because it points to momentum and a favorable Zacks Rank #1.
🍭 Bonus (B): 0/10 — Office Machines

🏢 What they do: Metallus Inc. manufactures specialty steel and metal products, including alloy steel bars, seamless mechanical tubing, precision steel components, and billets. Its products are used in demanding industrial, automotive, aerospace & defense, and energy applications.
- 🎯 Current $19.99 is 17% below 3yr high $24.02 · ⏳ SMA200 $18.13 (current price $19.99 is above) · 💰 Market Cap $999M
- MTUS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 333% (>20%); Low LT D/E 0.00 (<1.0); PEG ratio 0.86 (<1.5).
⏰ Entry (E): 0/20
- ⚠️ SMA20/SMA50 bearish crossover
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ Metallus (MTUS) Tops Q1 Earnings and Revenue Estimates — Zacks.
🤖 Metallus reported Q1 earnings of $0.18 per share versus the $0.13 consensus estimate and beat revenue expectations as well. Beating both earnings and revenue estimates is typically supportive for the stock.
⚪️ Metallus Announces Second-Quarter 2026 Earnings Webcast Details — PR Newswire.
🤖 This is a routine investor-relations announcement that Metallus will release Q2 2026 results on August 3 and hold a conference call on August 4. It does not provide actual results, guidance, or analyst commentary, so it is not directly positive or negative for the stock.
🍭 Bonus (B): 0/10 — Steel Works & Blast Furnaces

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 Current $54.98 is 4% below 3yr high $57.10 · ⏳ SMA200 $45.05 (current price $54.98 is above) · 💰 Market Cap $13.9B
- EXEL shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (10.3% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 44% (>20%); ROE 43% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 53 in healthy mid-range
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ Exelixis Inc stock hits all-time high at 56.22 USD — Investing.com.
🤖 The article says EXEL reached an all-time high and had strong recent gains, which signals bullish investor sentiment. It also cites analyst updates and trial-related momentum that support a constructive near-term view.
✅ EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth? — Yahoo Finance / Zacks.
🤖 This piece highlights strong recent share performance and outperformance versus the broader market. Its framing is bullish, suggesting further upside potential for the stock.
⚪️ Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026 — Business Wire.
🤖 This is only an earnings-date announcement and does not provide results, guidance, or analyst commentary. Per your rules, it has no material stock-specific signal and would normally be omitted, but it is not included in the final list.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Hewlett Packard Enterprise (HPE) is an enterprise technology company that provides compute, storage, networking, and software solutions designed for hybrid IT environments and AI infrastructure.
- 🎯 Current $48.13 is 14% below 3yr high $56.15 · ⏳ SMA200 $28.47 (current price $48.13 is above) · 💰 Market Cap $63.7B
- HPE shows decent technicals supported by positive sentiment.

💎 Quality (Q): 47/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 154% (>20%); Revenue growth 40% (>15%); Low LT D/E 0.86 (<1.0); PEG ratio 0.29 (<1.5).
⏰ Entry (E): 2/20
- 🔔 Strong above EMA50 (13.1%)
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Why Is Hewlett Packard Enterprise (HPE) Down 19.7% Since Last Earnings Report? — Yahoo Finance.
🤖 The article highlights raised fiscal 2026 revenue and EPS guidance, an improved free-cash-flow outlook, and a new fiscal 2027 framework, all of which are supportive for the stock. It also notes upward estimate revisions and a Zacks Strong Buy rating.
✅ Dell and Hewlett Packard Enterprise Shares Skyrocket ... — Yahoo Finance.
🤖 This piece says HPE shares jumped after IBM's revenue warning signaled stronger enterprise IT spending toward server and memory purchases. That macro read-through is favorable for HPE's hardware demand.
⚪️ Getty Images, SAIC, Cognex, Hewlett Packard Enterprise ... — Yahoo Finance.
🤖 The article mainly notes that HPE rose 3.6% alongside other stocks and does not provide a company-specific catalyst or fundamental development. It is therefore neutral for the stock.
🍭 Bonus (B): 10/10 — Computer & Office Equipment (Technology sector)

🏢 What they do: BrightSpring Health Services (BTSG) is a leading provider of comprehensive home and community-based health services, including clinical, nonclinical, pharmacy, and ancillary care, to complex populations across all ages and skill levels. It operates as the parent company of brands focused on specialized care in home and community settings, emphasizing quality outcomes for people with complex needs.
- 🎯 Current $69.74 is 4% below 3yr high $72.56 · ⏳ SMA200 $44.39 (current price $69.74 is above) · 💰 Market Cap $13.5B
- BTSG shows decent technicals supported by positive sentiment.

💎 Quality (Q): 53/60
- 🏦 Low drawdown (9.3% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 379% (>20%); Revenue growth 26% (>15%); ROE 16% (>15%).
⏰ Entry (E): 5/20
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (57) — BEARISH
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Jennison Associates LLC Purchases Shares of 19354 BrightSpring Health Services, Inc. (BTSG) — MarketBeat.
🤖 This is positive because it reports an institutional investor buying BTSG shares, which can signal confidence in the stock. The article also notes a consensus Buy rating and an average target price above the current market context implied by the filing.
✅ BTSG Stock Gains on Q1 Earnings & Revenue Beat, 2026 Outlook ... — Zacks.
🤖 This is positive because BrightSpring beat first-quarter 2026 adjusted EPS and revenue expectations, and the article says the company raised its 2026 outlook. Better-than-expected results and higher guidance are typically supportive for the stock.
🍭 Bonus (B): 0/10 — Home Health Care Services

🏢 What they do: Ooma, Inc. provides cloud-based VoIP phone systems and unified communications services for businesses and consumers, featuring voice, messaging, video, and AI tools like call transcriptions and answering services. Their primary offerings include Ooma Office for small to mid-sized businesses, Ooma AirDial for POTS line replacement, and Ooma Telo for affordable residential landline service.
- 🎯 Current $20.24 is 4% below 3yr high $20.97 · ⏳ SMA200 $14.14 (current price $20.24 is above) · 💰 Market Cap $555M
- OOMA shows favorable technicals but negative sentiment warrants caution.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (14.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1000% (>20%); Revenue growth 25% (>15%); Low LT D/E 0.50 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 3/10
- 🗞️ News sentiment is negative (mixed coverage).
✅ Ooma, Inc. (NYSE:OOMA) Receives Consensus Recommendation of Moderate Buy From Brokerages — MarketBeat.
🤖 This analyst update is positive because it shows covering brokers collectively rate Ooma as a Moderate Buy, with four Buy ratings and an average price target of about $22.33. That implies continued upside expectations for the stock.
❌ Ooma CEO Eric Stang sells $464240 of Ooma stock — Investing.com.
🤖 This is mildly negative because a CEO share sale can signal insider selling pressure, even though the article also notes Ooma recently beat earnings and raised outlook. The insider transaction is the main stock-specific negative element.
❌ Ooma (NYSE:OOMA) SVP Jenny Yeh Sells 2481 Shares — MarketBeat.
🤖 This is mildly negative because it reports another insider sale, which can weigh on sentiment. The article also references strong recent earnings and a Moderate Buy consensus, but the insider transaction itself is the bearish feature.
🍭 Bonus (B): 10/10 — Computer Processing & Data Prep (Technology sector)

🏢 What they do: John Wiley & Sons, Inc. (Wiley) is a global research and learning company that publishes over 1,900 peer-reviewed scientific, technical, medical, and scholarly journals along with academic and professional books, encyclopedias, and digital content .
- 🎯 Current $49.47 is 7% below 3yr high $53.13 · ⏳ SMA200 $37.59 (current price $49.47 is above) · 💰 Market Cap $2.6B
- WLY shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (8.9% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 103% (>20%); ROE 26% (>15%); Low LT D/E 0.81 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 54 in healthy mid-range
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Wiley Raises Dividend for 33rd Consecutive Year, Powered by Research and AI Momentum, Record Margins, and Strong Cash Flow — Business Wire.
🤖 Wiley said its board approved a dividend increase for the 33rd straight year and pointed to record margins and strong cash flow. The company also framed the raise around research and AI momentum, which is generally supportive for the stock.
✅ The Bull Case For John Wiley & Sons (WLY) Could Change Following 33rd Straight Dividend Hike And Earnings Update — Yahoo Finance.
🤖 This article highlights Wiley’s dividend increase and recent earnings update, including reported fourth-quarter sales and full-year net income. The dividend growth and profitable results are positive signals for income-oriented investors and can support the stock.
🍭 Bonus (B): 0/10 — Book Publishing